Clinical Trial Update: Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh [Phase 4]

View source ↗

Summary

Phase 4 safety update examining the risk of tuberculosis and other infections in Bangladeshi patients with spondyloarthritis treated with tofacitinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spondyloarthritis

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Conditions: Spondyloarthritis | Phase 4 | Status: UNKNOWN